Back |
home / stock / mrsn / mrsn message board
Subject | By | Source | When |
---|---|---|---|
Thanks for the updates jaybe | dorothy52 | investorshub | 03/07/2018 10:40:47 PM |
Article in ADC Review notes Mersana's progress... | jaybe | investorshub | 02/03/2018 11:05:16 PM |
Notes from$ JPM: Moving forward on all fronts... | jaybe | investorshub | 01/12/2018 4:15:57 PM |
Poster from today's presentation at AACR-EORTC available here... | jaybe | investorshub | 10/29/2017 7:25:11 PM |
Okay I get it. Wonder how trial is | dorothy52 | investorshub | 10/03/2017 11:44:16 PM |
Thats $2B in bio-bucks right? This will be | jaybe | investorshub | 10/03/2017 11:00:36 PM |
There's about 25 million shares right? So with | dorothy52 | investorshub | 10/03/2017 9:17:51 PM |
PEs are all over the map, I mean | jaybe | investorshub | 10/03/2017 6:55:10 PM |
All green for me as well. 10 bagger? | dorothy52 | investorshub | 10/03/2017 6:16:11 PM |
Mersana picks up 'Best New Drug Developer' at | jaybe | investorshub | 09/23/2017 2:06:48 AM |
Should see analyst coverage Monday...expiration of quiet period.. | jaybe | investorshub | 07/22/2017 2:19:00 AM |
$MRSN...all green lights for me... | jaybe | investorshub | 07/16/2017 6:36:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...